Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug ITU512 aims to boost fetal hemoglobin in sickle cell patients

NCT ID NCT06546670

First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 25 times

Summary

This early-stage study tests a new drug called ITU512 in healthy people and those with sickle cell disease. The goal is to see if it is safe and can increase fetal hemoglobin, which may reduce sickle cell complications. About 161 participants will take part, starting with healthy volunteers and then moving to patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Boston Childrens Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Lifespan

    RECRUITING

    Providence, Rhode Island, 02903, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Quotient Sciences Sea View

    COMPLETED

    Miami, Florida, 33126, United States

  • University of Alabama Birmingham

    RECRUITING

    Birmingham, Alabama, 35233, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.